Health & Environmental Research Online (HERO)


Print Feedback Export to File
8308014 
Journal Article 
Determination of erythromycin cyclic 11,12-carbonate in human plasma by LC-MS/MS method 
Lin, FF; Chen, XY; Dai, XJ; Zhong, DF 
2010 
0 
Zhongguo Yaoxue Zazhi
ISSN: 1001-2494 
45 
13 
1020-1023 
Chinese 
OBJECTIVE: To develop a liquid chromatography-tandem mass spectrometric (LC-MS/MS) method for the determination of erythromycin cyclic 11,12-carbonate in human plasma. METHODS: An aliquot of 50 μL plasma sample was extracted by n-hexane-dichloromethane-isopropanol (300:150:15), then separated on a Capcell Pak C18 MG (2.0 mm x 35 mm, 3 μm) column using methanol-5 mmol·L-1 ammonium acetate-formic acid (75:25:0.2). A tandem mass spectrometer equipped with electrospray ionization source was used as detector and operated in the positive ion mode. Quantification was performed using multiple reaction monitoring (MRM) of the transitions m/z 761→m/z 158 and m/z 838→m/z 158 for erythromycin cyclic 11,12-carbonate and internal standard roxithromycin as internal standard, respectively. RESULTS: The linear calibration curves were obtained in the concentration range from 1.00 to 2 000 ng·mL-1. The low limit of quantification was 1.00 ng·mL-1, and the sensitivity was elevated by at least 20 times compared with the methods mentioned in the literature. The intra-day and inter-day relative standard deviation over the entire concentration range was below 9.6%. The accuracy was within ±0.9% in terms of relative error. The mean recovery was 80.4% and 79.3% for erythromycin cyclic 11,12-carbonate and internal standard roxithromycin, respectively. The total chromatographic run time was 2.5 min. CONCLUSION: This method was sensitive, selective and rapid, and suitable to evaluate the bioequivalence of two erythromycin cyclic 11,12-carbonate tablets. 
Bioequivalence; Erythromycin cyclic 11,12-carbonate; Liquid chromatography-tandem mass spectrometry; Plasma concentration